Young-Jin Kim
Chief Executive Officer at HANDOK INC.
Net worth: 19 M $ as of 2024-04-29
Profile
Young-Jin Kim is currently serving as the Chairman & Co-Chief Executive Officer at Handok, Inc. since 1996.
He is also a Non-Executive Director at Genexine, Inc. since 2015 and a Director at Rezolute, Inc. since 2022.
Additionally, he holds the position of Vice President at The Korea Chamber of Commerce & Industry since 2009.
Mr. Kim is the President of Handok Jeseok Foundation since 2014 and the President of Korean German Society since 2010.
In his former positions, Mr. Kim served as the Chief Executive Officer at Hoechst Marion Roussel, Inc. He was also the Chief Executive Officer & Country Manager at Sanofi-Aventis Korea Co., Ltd.
from 1991 to 2005.
He held the position of Chief Executive Officer at Korea Hoechst Marion Roussel during the same period.
Mr. Kim was the Vice Chairman of Korea Pharmaceutical Manufacturers Association from 1999 to 2007.
He also served as a Director at pH Pharma Co., Ltd.
and the Korean German Chamber of Commerce & Industry from 2010 to 2016.
Furthermore, he was the Country Manager at Hoechst AG from 1991 to 2005.
Mr. Kim obtained an MBA from Kelley School of Business in 1984.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
HANDOK, INC.
13.65% | 2024-01-01 | 1,878,397 ( 13.65% ) | 19 M $ | 2024-04-29 |
REZOLUTE, INC.
0.29% | 2024-03-17 | 115,450 ( 0.29% ) | 300 170 $ | 2024-04-29 |
Young-Jin Kim active positions
| Companies | Position | Start |
|---|---|---|
| HANDOK INC. | Chief Executive Officer | 1995-12-31 |
| GENEXINE, INC. | Director/Board Member | 2015-03-19 |
| REZOLUTE, INC. | Director/Board Member | 2022-05-03 |
The Korea Chamber of Commerce & Industry
 The Korea Chamber of Commerce & Industry Miscellaneous Commercial ServicesCommercial Services The Korea Chamber of Commerce & Industry (KCCI) is a business organization that provides resources, publications, events, and networks for its members. The organization is based in Seoul, North Korea and has overseas offices. The KCCI advocates for its members and partners with other organizations to promote bilateral economic cooperation. The KCCI also provides economic data and policy issues publications and hosts business forums and roundtables. Recently, the KCCI hosted a successful business forum with over 600 attendees, including political and business leaders from both countries. The Financial Services Commission identified five bank holding companies and five banks as domestic systemically important banks for 2024, and those identified as D-SIBs are required to set aside an additional common equity capital of 1.0, and the higher loss absorbency requirement will take effect on January 1, 2024. | Corporate Officer/Principal | 2008-12-31 |
| Handok Jeseok Foundation | President | 2013-12-31 |
TRIGR Therapeutics, Inc.
 TRIGR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trigr Therapeutics, Inc. engages in pharmaceuticals industry group. The company is headquartered in Irvine, CA. | Director/Board Member | - |
| Korean German Society | President | 2009-12-31 |
Former positions of Young-Jin Kim
| Companies | Position | End |
|---|---|---|
| Korean German Chamber of Commerce & Industry | Director/Board Member | 2015-12-31 |
| Korea Pharmaceutical Manufacturers Association | Director/Board Member | 2006-12-31 |
| ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of Young-Jin Kim
| Kelley School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| HANDOK INC. | Health Technology |
| GENEXINE, INC. | Health Technology |
| REZOLUTE, INC. | Health Technology |
| Private companies | 11 |
|---|---|
pH Pharma Co., Ltd.
 pH Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology pH Pharma Co. Ltd. engages in the developing and manufacturing of bio-pharmaceuticals. Its products include php-303, php-201, ab-101, nuvesse, alpine and torpedo products. The company was founded by Ho Young Huh on September 22, 2015 and is headquartered in Seoul, South Korea. | Health Technology |
Hoechst AG
 Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
Sanofi-Aventis Korea Co., Ltd.
 Sanofi-Aventis Korea Co., Ltd. Pharmaceuticals: MajorHealth Technology Sanofi-Aventis Korea Co., Ltd. provides pharmaceutical research and development services. Its products include prescription medicine, consumer health care, vaccines, and non-prescription medicine. The company founded in April 1991 and is headquartered in Seoul, South Korea. | Health Technology |
The Korea Chamber of Commerce & Industry
The Korea Chamber of Commerce & Industry Miscellaneous Commercial ServicesCommercial Services The Korea Chamber of Commerce & Industry (KCCI) is a business organization that provides resources, publications, events, and networks for its members. The organization is based in Seoul, North Korea and has overseas offices. The KCCI advocates for its members and partners with other organizations to promote bilateral economic cooperation. The KCCI also provides economic data and policy issues publications and hosts business forums and roundtables. Recently, the KCCI hosted a successful business forum with over 600 attendees, including political and business leaders from both countries. The Financial Services Commission identified five bank holding companies and five banks as domestic systemically important banks for 2024, and those identified as D-SIBs are required to set aside an additional common equity capital of 1.0, and the higher loss absorbency requirement will take effect on January 1, 2024. | Commercial Services |
| Handok Jeseok Foundation | |
TRIGR Therapeutics, Inc.
TRIGR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trigr Therapeutics, Inc. engages in pharmaceuticals industry group. The company is headquartered in Irvine, CA. | Health Technology |
| Korea Hoechst Marion Roussel | |
| Korea Pharmaceutical Manufacturers Association | |
| Korean German Society | |
| Korean German Chamber of Commerce & Industry | |
| Hoechst Marion Roussel, Inc. |
- Stock Market
- Insiders
- Young-Jin Kim